Long-term effects of rasagiline and the natural history of treated Parkinson's disease

Movement Disorders

Volumn 31, Issue 10, 2016, Pages 1489-1496

  Rascol, Olivier ^a   Hauser, Robert A ^b   Stocchi, Fabrizio ^c   Fitzer Attas, Cheryl J ^d   Sidi, Yulia ^e   Abler, Victor ^e   Olanow, C Warren ^f  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Parkinson's Disease and Movement Disorders Center   (United States)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^e TEVA PHARMACEUTICALS   (Israel)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

disease progression; Parkinson's disease; Rasagiline

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; RASAGILINE;

ADD ON THERAPY; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BALANCE IMPAIRMENT; COGNITIVE DEFECT; COHORT ANALYSIS; COLON CANCER; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DIZZINESS; DRUG EFFECT; EARLY INTERVENTION; FAINTNESS; FALLING; FATIGUE; FEMALE; FOLLOW UP; GAIT DISORDER; HUMAN; INSOMNIA; LEG FRACTURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA; MONOTHERAPY; MOTOR UNIT; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; PAIN; PARKINSON DISEASE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; THERAPY DELAY; THORAX PAIN; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UNSTEADY GAIT;

EID: 84991208369     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26724     Document Type: Article

References (17)

1. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268–1278.
2. Writing Group for the NETiPDI, Kieburtz K, Tilley BC, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 2015;313(6):584–593.
3. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(Pt 4):861–870.
4. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129–2170.
5. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649–2653.
6. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24(4):564–573.
7. Poewe W, Mahlknecht P. The clinical progression of Parkinson's disease. Parkinsonism Relat Disord 2009;15(suppl 4):S28–S32.
8. Goetz CG. What's new? Clinical progression and staging of Parkinson's disease. J Neural Transm Suppl 2006(70):305–308.
9. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82(10):1112–1118.
10. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66(8):1200–1206.
11. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998;51(2):520–525.
12. Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology 2013;80(7):627–633.
13. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005;65(9):1436–1441.
14. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84(11):1258–1264.
15. Xia R, Mao ZH. Progression of motor symptoms in Parkinson's disease. Neurosci Bull 2012;28(1):39–48.
16. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415–423.
17. Vu TC, Nutt JG, Holford NH. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. Br J Clin Pharmacol 2012;74(2):284–295.